# CMND-100 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/cmnd-100

> The FDA approved CMND-100, sponsored by Clearmind Medicine Inc. (CMND), on July 31, 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | CMND-100 |
| Codes | CMND-100 |
| Sponsor | Clearmind Medicine Inc. (CMND) https://sec-api.dev/companies/cmnd/catalysts |
| Indications | [alcohol use disorder](https://sec-api.dev/indications/alcohol-use-disorder) |
| Modality |  |
| FDA designations | breakthrough |

## Timeline

### Feb 2024: FDA approval

- Status: completed, approved. Date confidence: month. Stage: 1.
- First seen 2026-09-10, last confirmed 2026-09-10.
- Press release filed with the SEC (EX-99) (accession 0001213900-26-098779): "In February 2024 and in July 2024, the Company announced that it was granted approval by the Israeli Ministry of Health and by the U.S. Food and Drug Administration, respectively to initiate its first-in-human Phase I/IIa clinical trial with CMND-100 in patients suffering from AUD." https://www.sec.gov/Archives/edgar/data/1892500/000121390026098779/ea030403301ex99-2.htm

### March 18, 2025: trial start

- Status: completed. Date confidence: exact. Stage: 1.
- First seen 2025-03-18, last confirmed 2025-04-10.
- Press release filed with the SEC (EX-99) (accession 0001013762-25-000571): "Canada, March 18, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces today that it initiated its Phase I/IIa clinical trial investigating the safety, tolerability and full pharmacokinetic profile of its innovative treatment, CMND-100, in Alcohol Use Disorder (AUD) patients." https://www.sec.gov/Archives/edgar/data/1892500/000101376225000571/ea023459001ex99-1_clearmind.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-030438): "NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced today that it has initiated its Phase I/IIa clinical trial at its first U.S. clinical site, the Johns Hopkins University School of Medicine." https://www.sec.gov/Archives/edgar/data/1892500/000121390025030438/ea023780902ex99-1_clearmind.htm

### April 30, 2025: FDA approval

- Status: completed, approved. Date confidence: exact. Stage: 1.
- First seen 2025-06-12, last confirmed 2025-06-12.
- Press release filed with the SEC (EX-99) (accession 0001213900-25-053839): "2024, the Company announced that it was granted approval by the Israeli Ministry of Health and by the FDA, respectively to initiate its first-in-human Phase I/IIa clinical trial with CMND-100 in patients suffering from AUD." https://www.sec.gov/Archives/edgar/data/1892500/000121390025053839/ea024453601ex99-2_clearmind.htm

### July 31, 2025: FDA approval

- Status: completed, approved. Date confidence: exact. Stage: 1.
- First seen 2025-09-11, last confirmed 2025-09-11.
- Press release filed with the SEC (EX-99) (accession 0001213900-25-086821): "2024, the Company announced that it was granted approval by the Israeli Ministry of Health and by the FDA, respectively to initiate its first-in-human Phase I/IIa clinical trial with CMND-100 in patients suffering from AUD." https://www.sec.gov/Archives/edgar/data/1892500/000121390025086821/ea025617001ex99-2_clearmind.htm

### November 18, 2025: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 1. Indication: Alcohol Use Disorder.
- First seen 2025-11-18, last confirmed 2025-11-18.
- Press release filed with the SEC (EX-99) (accession 0001213900-25-112114): "Canada, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced positive top-line results from the first cohort of its Phase I/IIa clinical trial evaluating CMND-100, the Company's proprietary non-hallucinogenic MEAI-based oral drug candidate for the treatment of Alcohol Use Disorder (AUD)." https://www.sec.gov/Archives/edgar/data/1892500/000121390025112114/ea026618401ex99-1_clearmind.htm

### February 9, 2026: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 1.
- First seen 2026-02-09, last confirmed 2026-02-09.
- Press release filed with the SEC (EX-99) (accession 0001213900-26-013478): "Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced additional positive safety topline results from the second cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the" https://www.sec.gov/Archives/edgar/data/1892500/000121390026013478/ea027611302ex99-1_clearmind.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/cmnd-100.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CMND-100 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/cmnd-100

```bibtex
@misc{secapidev_pdufa_cmnd_100_20261116,
  title        = {CMND-100 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/cmnd-100}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_cmnd_100_20261116","title":"CMND-100 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/cmnd-100","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
